Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of AMT-253 in unresectable or metastatic malignant melanoma and other solid tumors
CTR20234311Phase 2Active
- Sponsor
- PuZhong Discovery
- Start
- Mar 2024
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of AMT-253 CAR-T cells in melanoma, Cervical Cancer (CC), uterine leiomyosarcoma (uLMS), ovarian cancer, endometrial cancer (EC), sponsored by PuZhong Discovery. Started Mar 2024; status: active.
02
Drugs
AMT-253 CAR-T cells
03
Conditions
melanomaCervical Cancer (CC)uterine leiomyosarcoma (uLMS)ovarian cancerendometrial cancer (EC)
Beyond the preview
Go deeper on CTR20234311.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20234311.